1. Introduction {#s0005}
===============

*Culex pipiens* mosquitoes play an important role in the transmission of pathogens of significant public and veterinary health importance. They are the primary vectors of the Saint Louis Encephalitis in the USA and the West Nile Virus (WNV, *Flaviviridae*, *Flavivirus*) in Europe and the USA ([@bb0040], [@bb0010], [@bb0120]). WNV is normally maintained through a bird-mosquito cycle but can be spread to a wide range of incidental hosts, such as horses and humans, where it causes severe neurological disorders ([@bb0080], [@bb0005]). *Culex pipiens* is one of the main vectors of the zoonotic filarial agents *Dirofilaria immitis* (heartworm) and *Dirofilaria repens* (subcutaneous filarial worm) ([@bb0070], [@bb0020], [@bb0095]). *Dirofilaria repens* is responsible for subcutaneous dirofilariosis in dogs and is often associated with mild signs or subclinical infections, such as localized itching, mild skin lesions, or subcutaneous nodules in different body areas ([@bb0130]). *Dirofilaria immitis* on the contrary causes severe disorders and even death in dogs in many parts of the world ([@bb0090]). In humans, ocular, subcutaneous and pulmonary forms of *D. immitis* and *D. repens* have been reported ([@bb0090], [@bb0110], [@bb0115], [@bb0065]).

Therefore it is important to establish an integrated control programme against these mosquitoes to prevent pathogen transmission to humans and animals in endemic areas. Integrated programmes include the use of mosquito repellents, and one current approach involves the use of existing molecules in combination ([@bb0135], [@bb0030], [@bb0050]). Pyrethroids such as permethrin and deltamethrin have a recognized efficacy against sandflies and mosquitoes, and have been used widely in companion animals ([@bb0100], [@bb0015]). Dinotefuran is a rapid-acting nitroguanidine furanicotinyl insecticide, representing a third generation of neonicotinoid. It exerts its action on an acetylcholine receptor present in the insect nerve synapse by mimicking the action of the neurotransmitter ([@bb0145]). Pyriproxyfen is an analogue of the insect juvenile hormone. In mosquitoes, pyriproxyfen inhibits the metamorphosis by preventing the emergence of adults from pupae ([@bb0105], [@bb0150]). This juvenile hormone analogue has been widely used in the control of mosquitoes (*i.e. Aedes* sp., *Culex* sp., and *Anopheles* sp.) especially in malaria endemic areas ([@bb0060], [@bb0085], [@bb0125]). A formulation combining dinotefuran, permethrin and pyriproxyfen (Vectra® 3D, Ceva, France) was launched in the USA in 2007 and in Europe in 2014. It is indicated for the prevention and treatment of fleas, ticks, flies sandflies and mosquitoes in dogs. This combination has already shown a good efficacy against the mosquito species *Aedes aegypti* ([@bb0045]).

The aim of the study was to evaluate the adulticidal and the repellent effects of Vectra® 3D on *Culex pipiens* in dogs.

2. Materials and methods {#s0010}
========================

The study was conducted at the National Veterinary School of Toulouse (Ecole Nationale Vétérinaire de Toulouse, ENVT), France, according to the Good Clinical Practices (GCP study). The protocol was approved by the local Ethics Committee and dogs were handled in accordance with the animal welfare and the local Institutional Animal Care and Use Committee requirements (ethical clearance MP/14280312). All personnel involved with the collection of efficacy data were blinded to the treatment.

2.1. Dogs {#s0015}
---------

Twelve Beagle dogs (six females and six males aged between 2 and 10 years and weighing between 9.01 and 12.95 kg) were included in the study and acclimatized to the trial environment for 38 days prior to treatment. They had not been exposed to short-acting ectoparasiticides for 3 months prior to the inclusion and had never been treated with any long-acting ectoparasiticides. They were housed in individual boxes and had a four-hour daily access to a 4 × 4 m concrete run where they could run and play with toys. Control and treated dogs were placed in two different exercise areas to avoid cross contamination. Dogs were observed daily for their general health conditions and remained in good health throughout the study.

On Day - 28 each dog was challenged with 80 unfed adult *Culex pipiens* females to assess their receptivity to mosquitoes. The number of engorged female mosquitoes was used for allocation to groups. Dogs were ranked in descending order of their individual mosquito\'s engorgement status and six blocks of two animals each were formed. Within blocks, dogs were randomly allocated to the treatment or control group.

2.2. Mosquito maintenance and supply {#s0020}
------------------------------------

The *Culex pipiens* female mosquitoes used in this trial were reared at the ENVT laboratory and were 15-day old when used for infestation. The colony was originated from the Interdepartmental agreement for Mosquito Control on the Mediterranean coast (Entente Interdépartementale de Démoustication, EID), Montpellier, France, and was maintained at ENVT under laboratory conditions since 2001.

2.3. Treatment {#s0025}
--------------

The six dogs from the control group were not treated, and the other six received on Day 0 a topical combination of dinotefuran, pyriproxyfen and permethrin. They were treated with the commercial dose of the product based on their bodyweight (1.6 mL pipette for dogs weighing between 4.1 and 10.0 kg and 3.6 mL pipette for dogs weighing between 10.1 and 25 kg). Dogs were administered 0.23 ± 0.08 mL/kg BW of the solution corresponding to 12.67 mg/kg ± 4.08 of dinotefuran, 92.33 mg/kg ± 29.77 of permethrin and 1.13 mg/kg ± 0.36 of pyriproxyfen. The formulation was applied directly onto the skin according to the manufacturer\'s instructions: in two points for the 1.6 mL pipette (between shoulder blades and on the lumbar area) and in three points for the 3.6 mL pipette (between shoulder blades, on the dorsal midline and on the lumbar area). The formulation was provided by CEVA Animal Health.

All dogs were observed at 2 and 4 h after treatment for any adverse reaction to the product.

2.4. Experimental procedure {#s0030}
---------------------------

The 12 dogs were infested with 80 (± 2) *C. pipiens* females on Days - 28, 1, 7, 14, 21 and 28. Before exposure, dogs were sedated by intramuscular injection of a mixture of medetomidine (Dexdomitor®, Pfizer Santé animale, Paris, France) and ketamine (Imalgène 1000®, Laboratoire Mérial, Lyon, France) at a dose rate of 5 μg/kg and 5 mg/kg respectively. Once sedated they received an intramuscular injection of diazepam (Valium®, Roche injectable, Neuilly s/ Seine, France) at a dose rate of 0.5 mg/kg, before they were placed in the individual nets containing mosquitoes. The dosage of the anaesthetic was calculated so as to immobilize dogs for 90 min and additional amount of the products were administered when needed.

Two days before exposure, mosquitoes were aspirated from their breeding cage with a vacuum pump and then placed in each challenge net. They were provided cottons soaked with water and had honey at their disposal. They were fasted 24 h before exposure to dogs by removing honey from each infestation net. The cottons soaked with water were removed at the introduction of the dogs. During exposure to mosquitoes, treated and controlled dogs were placed in two separated infestation rooms where temperature and relative humidity were maintained at 25 °C ± 3 °C and 60% ± 5% respectively. The light was turned off during the hour of exposure.

After 90 ± 5 min of exposure, the dogs were carefully taken out of the net and examined for any dead mosquito on their body, and then were returned to their individual box. Live mosquitoes were aspirated from each net and were classified as live engorged or live non-engorged. The engorgement status was determined by observation of the abdomen distension and the presence of blood in it with the naked eye. All dead mosquitoes were collected and classified as dead engorged or dead non-engorged. Remaining live mosquitoes recovered from each dog were placed in separate nets and kept in the experimental room. They were checked for mortality 24 h after. Then, all remaining mosquitoes were discarded.

After each mosquito challenge, cages and nets were thoroughly cleaned.

2.5. Data analysis {#s0035}
------------------

### 2.5.1. Antifeeding effect or repellency {#s0040}

For each time point after exposure, the antifeeding effect was calculated as described below:$$\text{Anti} - \text{feeding\ effect} = 100 \times \frac{{Ce}‐{Te}}{Ce}$$

Ce stands for the arithmetic mean of engorged females mosquitoes (live engorged + dead engorged) for the controlled group and Te is the arithmetic mean of engorged female mosquitoes for the treated group.

### 2.5.2. Mortality effect (or insecticidal effect) {#s0045}

For each time point after exposure, the mortality effect was evaluated for each group as described below:$$\text{Mortality\ effect} = 100 \times \frac{{Cl}‐{Tl}}{Cl}$$

Cl stands for the arithmetic mean of live females mosquitoes (live engorged + live unengorged) for the controlled group and Tl was the arithmetic mean of live female mosquitoes for the treated group.

The mortality effect was calculated at 90 min and 24 h post-exposure.

2.6. Statistical analysis {#s0050}
-------------------------

The two groups were compared for the number of engorged females and the number of dead females at each challenge point. They were subjected to general linear model (GLM) procedures (split model) with the software Systat 12.0 (Systat, USA) to determine the effect of 3 factors: group (treated or control group), day of examination and dog (as random factor) and the interaction Group ∗ Day on the numbers of mosquitoes engorged or dead at 1.5 h and 24 h after their exposition to dogs. Means were separated with the Tukey\'s honest significance test (Systat 12.0). Insect capture data were transformed with square root prior to analysis and back transformed values are given in text and tables. Differences were considered significant at *p* \< 0.05.

3. Results {#s0055}
==========

The treatment was well tolerated and no adverse events were reported. According to the GLM results, the Group and Day effects were significant as well as associated interaction Group ∗ Day (*p* \< 0.05) but not the Dog effect (*p* \> 0.05).

3.1. Anti-feeding effect (or repellency) on mosquitoes {#s0060}
------------------------------------------------------

The 12 dogs included in the study demonstrated a good pre-treatment parasite holding ability or receptivity: above 50% of engorged females per dog ([Fig. 1](#f0005){ref-type="fig"}). On Day-28, the mean number of engorged female mosquitoes was 66.3 and 66 out of 80 for the control and treatment group respectively. All control dogs maintained an adequate number of engorged females (*i.e.* mean number above 55) throughout the study ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Mean number of engorged *Culex pipiens* females after 90 min exposure to control and treated dogs.Dogs from treated group received on Day 0 a spot-on combination of dinotefuran, permethrin and pyriproxyfen (Vectra® 3D), dogs from controlled group remained untreated. All dogs were weekly challenged with 80 *Culex pipiens* females.At each challenge point after treatment, the differences between groups were statistically significant (*p* \< 0.05).\*\*\* represents statistical differences at *p* \< 0.0001.Fig. 1

The treatment had an anti-feeding effect above 98.6% for the first three expositions post-treatment (first two weeks) and remained above 96.7% until the end of the trial ([Table 1](#t0005){ref-type="table"}). At each challenge point post-treatment the difference in the engorgement status of *C. pipiens* females between treated and controlled group was significant (*p* \< 0.05).Table 1Mortality and anti-feeding effect of a dinotefuran, permethrin and pyriproxyfen spot-on combination (Vectra® 3D) against *Culex pipiens* females on dogs.Table 1Day 1Day 7Day 14Day 21Day 28Anti-feeding effect (%)\
(95%CI)1.5 h98.9 (93--100)98.8 (92.6--100)98.6 (92--100)96.7 (86.6--100)97.9 (89.8--100)Mortality effect (%)\
(95%CI)1.5 h34.7 (7.8--61.6)50.3 (22--78.6)39.7 (12--67.4)22.8 (0--46.5)11.4 (0.-29.4)24 h40.2 (12.5--67.9)51.0 (22.7--79.3)41.2 (13.4--69)22.3 (0--45.9)34.8 (7.8--61.8)

3.2. Mortality effect (or insecticidal effect) on mosquitoes {#s0065}
------------------------------------------------------------

The mortality effects of the treatment calculated at 1.5 h and 24 h post-exposure to treated dogs are reported in [Table 1](#t0005){ref-type="table"}. The mortality effect observed at 1.5 h ranged between 34.7% and 50.3% for the first two weeks after treatment and then dropped to values ranging between 11.4% and 22.8% for the last two expositions. The mortality effect of the formulation did not increase significantly within the 24 h post-exposure ([Table 1](#t0005){ref-type="table"}). At each challenge point, there was a significant difference (*p* \< 0.05) in the number of dead mosquitoes found at 1.5 h and 24 h of exposure between the treated and controlled group.

4. Discussion {#s0070}
=============

The results of this study showed that a single topical application of a combination of dinotefuran 4.95% (*w*/w), pyriproxyfen 0.44% (*w*/w) and permethrin 36.08% (*w*/w) (Vectra® 3D, Ceva, Libourne, France) provided an excellent feeding inhibition of *Culex pipiens* mosquitoes which lasted for four weeks. The combination provided a strong immediate effect with a 98.9% repellency reached 24 h after treatment. This efficacy remained above 96.7% for 28 days.

Recent studies reported the efficacy of other combinations containing permethrin combined with fipronil (Effitix®, Frontline Tri-Act®/Frontect®) on the same target, *Culex pipiens* ([@bb0030], [@bb0050]). The feeding inhibition provided by Vectra® 3D was similar or even better to the one obtained with these both new spot-on formulations containing approximately the same dose of permethrin. The repellency of Effitix® against *C. pipiens* was 100% (Day 1), 99.5% (Day 7), 97.7% (Day 14), 98.3% (Day 21) and 96.7% (Day 28) ([@bb0050]) while the efficacy of Frontline Tri-Act®/Frontect® was a bit lower with 99.4% (Day 1), 98.9% (Day 7), 94.7% (Day 14), 91.7% (Day 21) and 90.4% (Day 28) ([@bb0030]).

The efficacy of Vectra® 3D was investigated in a previous study on another mosquito strain, *Aedes aegypti*, under the same laboratory conditions ([@bb0045]). The repellency reached 91.5% on Day 1, 94% on Days, 7, 14 and 21 and 87% on Day 28, which was close to the repellency obtained with *C. pipiens*. However differences in insecticidal efficacies were observed between these two mosquito species. Vectra® 3D presented an insecticidal efficacy against *C. pipiens* remaining between 50.3% (Day 7) and 11.4% (Day 28). On the contrary, the insecticidal efficacy against *A. aegypti* was significantly higher (*i.e.* \> 93%) despite a shorter exposure time to treated dogs (60 *versus* 90 min) ([@bb0045]). Interestingly, similar discrepancies were obtained by [@bb0030] with permethrin combined with fipronil (Frontline Tri-Act®/Frontect®) against *C. pipiens* and *A. aegypti*. The authors obtained an insecticidal efficacy against *C. pipiens* of 77.9%, 92.1%, 34.7%, 38.5% and 26.9% on Days 2, 8, 15, 22 and 29 while the insecticidal efficacy obtained against *A. aegypti* was 99.8%, 93.8%, 69.5%, 77% and 20.9% on Days 1, 7, 14, 21 and 28 respectively. They suggested that the repellent effect of permethrin combined with fipronil was stronger on *C. pipiens* than on *A. aegypti* therefore preventing them from landing on the treated dogs, thus limiting the contact with the insecticidal molecules. However, there is currently no clear explanation on these differences of susceptibility between these two mosquito species. [@bb0075] investigated the literature review of repellency studies conducted on different products (DEET, Icaridin, Insect Repellent and plant-derived products (Citriodora or paramenthane-3,8-diol)) against *Anopheles* sp., *Culex* sp. and *Aedes* sp. regarding human skin. All the tested molecules provided a better repellency (anti-feeding effect) on *Culex* sp. than on *Anopheles* sp. or *Aedes* sp. The authors reported also that *Aedes* sp. demonstrated a more aggressive biting behaviour than *Culex* sp. This aggressive behaviour has also been observed in our experimental conditions in which dogs were infested with mosquitoes. Once in contact with dogs, *A. albopictus* or *A. aegypti* land and bite more promptly than *C. pipiens* that take longer before tempting to feed (authors\' personal observations). This behaviour could explain that the contact duration of *Aedes* sp. mosquitoes with the treated skin is increased, therefore improving the insecticidal efficacy (or mortality effect) of the molecule. A further reason could be related to the different feeding preferences of *C. pipiens* in comparison to *Aedes* sp: *C. pipiens* feeds preferentially on avian hosts while *Aedes*, especially *A. albopictus*, tends to feed predominantely on mammals including humans and pets ([@bb0055], [@bb0035], [@bb0140]). However, further behavioural studies would be necessary to investigate this difference in host attractancy under laboratory conditions. These observations would bring significant inputs to the design of repellency studies using mosquitoes, as the exposure duration to the hosts must be long enough to allow a good feeding rate on control animals.

Vectra® 3D is currently the only ectoparasiticidal combination for dogs containing dinotefuran. This molecule has a low affinity for binding sites of other neonicotinoid insecticides and has no cross-resistance with common parasiticides, such as permethrin ([@bb0145]). Therefore, dinotefuran has been proposed as a potential candidate for vector control in areas with resistance of mosquitoes to other insecticides ([@bb0025]).

5. Conclusion {#s0075}
=============

A combination of dinotefuran, pyriproxyfen and permethrin provides a good protection (*i.e.* a repellency above 96.7%) against *Culex pipiens* in dogs for one month following a single topical application. Therefore this treatment could be included in an integrated prevention program against heartworm disease for dogs living in or travelling to dirofilariosis endemic areas. However, it should not be seen as a substitute for heartworm prevention treatments.
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